Atavistik Bio to present the discovery and characterization of novel allosteric JAK2 V617F selective inhibitors that suppress mutant-dependent signaling and proliferation while sparing wild-type JAK2 ...
Proceeds will support the advancement of Atavistik Bio’s oral allosteric AKT1-selective inhibitor for Hereditary Hemorrhagic Telangiectasia (HHT) and the JAK2 V617F mutant-selective inhibitor program ...
LOS ANGELES--(BUSINESS WIRE)--Laekna (2105.HK) announced that the U.S. Food and Drug Administration (FDA) has approved the IND for LAE120, an internally discovered USP1 inhibitor, for the treatment of ...
Esperion announced the expansion of its development portfolio with a new program aimed at treating primary sclerosing cholangitis (PSC), a rare liver disease. The company confirmed the effectiveness ...
Lynk Pharmaceuticals Co. Ltd. has received IND clearance from the FDA for LNK-01006, an allosteric TYK2 inhibitor with potential to treat neurodegenerative diseases.
CARMEL, Ind.--(BUSINESS WIRE)--Sudo Biosciences (“Sudo”), a biopharmaceutical company committed to designing and developing best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, announced today ...
LEHI, Utah, Nov. 10, 2025 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class anti-inflammatory therapies, today announced six poster presentations ...
Relay Therapeutics leads with RLY-2608, an allosteric PI3Kα inhibitor showing superior safety and efficacy in advanced breast cancer. RLY-2608’s phase 1/2 trial data demonstrates higher response rates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback